133 related articles for article (PubMed ID: 34783301)
1. Anthracycline-induced cardiotoxicity in women without cardiovascular diseases: molecular and genetic predictors.
Kopeva KV; Grakova EV; Shilov SN; Berezikova EN; Popova AA; Neupokoeva MN; Ratushnyak ET; Teplyakov AT
Acta Cardiol; 2022 Nov; 77(9):805-814. PubMed ID: 34783301
[TBL] [Abstract][Full Text] [Related]
2. [Anthra-cycline-Induced Cardiotoxicity: the Role of Genetic Predictors].
Kopeva KV; Grakova EV; Shilov SN; Popova AA; Berezikova EN; Neupokoeva MN; Ratushnyak ET; Teplyakov AT
Kardiologiia; 2023 May; 63(4):22-28. PubMed ID: 37165991
[TBL] [Abstract][Full Text] [Related]
3. Anthracycline-induced cardiotoxicity in diffuse large B-cell lymphoma: NT-proBNP and cardiovascular score for risk stratification.
Ferraro MP; Gimeno-Vazquez E; Subirana I; Gómez M; Díaz J; Sánchez-González B; García-Pallarols F; Martínez L; Ble M; Molina L; Belarte LC; Abella E; Elosua R; Comín-Colet J; Salar A
Eur J Haematol; 2019 Jun; 102(6):509-515. PubMed ID: 30972815
[TBL] [Abstract][Full Text] [Related]
4. Anthracycline-Induced Cardiotoxicity: The Role of Endothelial Dysfunction.
Grakova EV; Shilov SN; Kopeva KV; Berezikova EN; Popova AA; Neupokoeva MN; Ratushnyak ET; Teplyakov AT
Cardiology; 2021; 146(3):315-323. PubMed ID: 33596565
[TBL] [Abstract][Full Text] [Related]
5. Prognostic Impact of Global Longitudinal Strain and NT-proBNP on Early Development of Cardiotoxicity in Breast Cancer Patients Treated with Anthracycline-Based Chemotherapy.
Muckiene G; Vaitiekus D; Zaliaduonyte D; Zabiela V; Verseckaite-Costa R; Vaiciuliene D; Juozaityte E; Jurkevicius R
Medicina (Kaunas); 2023 May; 59(5):. PubMed ID: 37241185
[No Abstract] [Full Text] [Related]
6. Assessment of anthracycline-induced cardiotoxicity with biochemical markers.
Horacek JM; Pudil R; Jebavy L; Tichy M; Zak P; Maly J
Exp Oncol; 2007 Dec; 29(4):309-13. PubMed ID: 18199989
[TBL] [Abstract][Full Text] [Related]
7. Elevations in High-Sensitive Cardiac Troponin T and N-Terminal Prohormone Brain Natriuretic Peptide Levels in the Serum Can Predict the Development of Anthracycline-Induced Cardiomyopathy.
Bisoc A; Ciurescu D; Rădoi M; Tântu MM; Rogozea L; Sweidan AJ; Bota DA
Am J Ther; 2020; 27(2):e142-e150. PubMed ID: 30648987
[TBL] [Abstract][Full Text] [Related]
8. Serial measurements of NT-proBNP are predictive of not-high-dose anthracycline cardiotoxicity in breast cancer patients.
Romano S; Fratini S; Ricevuto E; Procaccini V; Stifano G; Mancini M; Di Mauro M; Ficorella C; Penco M
Br J Cancer; 2011 Nov; 105(11):1663-8. PubMed ID: 22068815
[TBL] [Abstract][Full Text] [Related]
9. N-terminal-proB-type natriuretic peptide as a marker for acute anthracycline cardiotoxicity in children.
Ekstein S; Nir A; Rein AJ; Perles Z; Bar-Oz B; Salpeter L; Algur N; Weintraub M
J Pediatr Hematol Oncol; 2007 Jul; 29(7):440-4. PubMed ID: 17609620
[TBL] [Abstract][Full Text] [Related]
10. Use of N-terminal pro-brain natriuretic peptide to assess left ventricular function after adjuvant doxorubicin therapy in early breast cancer patients: a prospective series.
Cil T; Kaplan AM; Altintas A; Akin AM; Alan S; Isikdogan A
Clin Drug Investig; 2009; 29(2):131-7. PubMed ID: 19133708
[TBL] [Abstract][Full Text] [Related]
11. The role of biomarkers and echocardiography in the evaluation of cardiotoxicity risk in children treated for leukemia.
Raluca Maniu D; Blag C; Popa G; Bota M; Vlad C; Cainap C; Balacescu O; Pop L; Cainap SS
J BUON; 2018 Dec; 23(7):122-131. PubMed ID: 30722121
[TBL] [Abstract][Full Text] [Related]
12. Polymorphisms rs4673 and rs28714259 in predicting anthracycline-mediated cardiotoxicity in patients with breast cancer.
Gvaldin GD; Timoshkina TN; Vladimirova L; Svetitskaya SY; Vaschenko VL
Klin Onkol; 2021; 34(6):463-466. PubMed ID: 34911332
[TBL] [Abstract][Full Text] [Related]
13. Cardiotoxicity of anthracycline (ANT) treatment in children with malignant tumors.
Hu H; Zhang W; Huang D; Yang Q; Li J; Gao Y
Pediatr Hematol Oncol; 2018 Mar; 35(2):111-120. PubMed ID: 29648903
[TBL] [Abstract][Full Text] [Related]
14. The role of TNF-α, Fas/Fas ligand system and NT-proBNP in the early detection of asymptomatic left ventricular dysfunction in cancer patients treated with anthracyclines.
Kouloubinis A; Sofroniadou S; Panoulas VF; Makaritsis K; Revela I; Karavolias G; Voudris V; Adamopoulos S
Int J Cardiol Heart Vasc; 2015 Mar; 6():85-90. PubMed ID: 28785633
[TBL] [Abstract][Full Text] [Related]
15. Changes in Cardiovascular Biomarkers With Breast Cancer Therapy and Associations With Cardiac Dysfunction.
Demissei BG; Hubbard RA; Zhang L; Smith AM; Sheline K; McDonald C; Narayan V; Domchek SM; DeMichele A; Shah P; Clark AS; Fox K; Matro J; Bradbury AR; Knollman H; Getz KD; Armenian SH; Januzzi JL; Tang WHW; Liu P; Ky B
J Am Heart Assoc; 2020 Jan; 9(2):e014708. PubMed ID: 31959034
[TBL] [Abstract][Full Text] [Related]
16. Cardiac biomarkers for the detection of cardiotoxicity in childhood cancer-a meta-analysis.
Michel L; Mincu RI; Mrotzek SM; Korste S; Neudorf U; Rassaf T; Totzeck M
ESC Heart Fail; 2020 Apr; 7(2):423-433. PubMed ID: 32069386
[TBL] [Abstract][Full Text] [Related]
17. Tetranectin as a potential novel prognostic biomarker in anthracycline-related cardiac dysfunction.
Kopeva KV; Grakova EV; Shilov SN; Berezikova EN; Bobyleva ET; Teplyakov AT
Heart Vessels; 2023 Oct; 38(10):1256-1266. PubMed ID: 37310463
[TBL] [Abstract][Full Text] [Related]
18. [Prognostic role of p53 gene polymorphism in risk assessment of anthracycline-induced cardiotoxicity].
Shilov SN; Teplyakov AT; Popova AA; Berezikova EN; Neupokoeva MN; Grakova EV; Valeeva AM; Tuleutaev SM
Kardiologiia; 2019 Aug; 59(7S):15-22. PubMed ID: 31441737
[TBL] [Abstract][Full Text] [Related]
19. Extracellular matrix remodeling in anthracycline-induced cardiotoxicity: What place on the pedestal?
Grakova EV; Shilov SN; Kopeva KV; Berezikova EN; Popova AA; Neupokoeva MN; Ratushnyak ET; Teplyakov AT
Int J Cardiol; 2022 Mar; 350():55-61. PubMed ID: 35007649
[TBL] [Abstract][Full Text] [Related]
20. Pharmacodynamic modeling of cardiac biomarkers in breast cancer patients treated with anthracycline and trastuzumab regimens.
de Vries Schultink AHM; Boekhout AH; Gietema JA; Burylo AM; Dorlo TPC; van Hasselt JGC; Schellens JHM; Huitema ADR
J Pharmacokinet Pharmacodyn; 2018 Jun; 45(3):431-442. PubMed ID: 29429038
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
